NCT06385106 · RECRUITING
Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease
This trial tests whether a non-invasive brain stimulation device, repetitive transcranial magnetic stimulation (rTMS), changes sleep and thinking in people with mild-to-moderate Alzheimer's. Some participants get real stimulation and others get a sham version for comparison. It is not a drug trial, and the phase is not applicable. Results would not show it works or is approved.
You may qualify if
- Participant meets 2014 IWG-2 criteria for hippocampal amnestic syndrome, typical of AD, with progressive episodic memory impairment confirmed by neuropsychology. Cerebrospinal fluid markers (Aβ40, Aβ42, T-tau, p-tau) consistent with AD, or AV-45 PET imaging showing significant cortical tracer retention, in line with AD pathophysiology.
- Age range: 55-80 years.
- No visual or hearing impairment.
- Right-handed.
- Han nationality.
- Signed informed consent.
- Reliable caregivers as information providers.
- MMSE score: 10-27; CDR: 0.5-2 points.
- If receiving approved AD treatment (e.g., acetylcholinesterase inhibitor or memantine), dose must be stable for ≥3 months prior to screening and unchanged unless medically necessary.
You're excluded if
- History of seizures or epilepsy diagnosis;
- Stroke history;
- Nervous system diseases causing brain dysfunction (schizophrenia, severe anxiety/depression, dementia, Huntington's, brain tumors, Parkinson's, metabolic encephalopathy, encephalitis, MS, epilepsy, brain trauma, hydrocephalus);
- Severe liver/kidney/lung dysfunction, anemia, gastrointestinal disease, arrhythmia, recent MI;
- Barbiturate/benzodiazepine use within 2 weeks;
- MRI/TMS contraindications (metallic implants);
- Systemic diseases causing cognitive impairment (hypothyroidism, folate/B12 deficiency, infections, alcohol/drug abuse);
- Aphasia, consciousness disturbance, inability to cooperate;
- TMS/tDCS/DBS has been processed;
- Underlying pathology other than AD;
- Focal brain lesions on T1/T2 images;
- Refusal to sign informed consent.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-05-11